

Contents

PI3K: From the Bench to the Clinic and Back	1
Bart Vanhaesebroeck, Peter K. Vogt, and Christian Rommel	
Oncogenic Mutations of PIK3CA in Human Cancers	21
Yardena Samuels and Todd Waldman	
Structural Effects of Oncogenic PI3Kα Mutations	43
Sandra B. Gabelli, Chuan-Hsiang Huang, Diana Mandelker, Oleg Schmidt-Kittler, Bert Vogelstein, and L. Mario Amzel	
Comparing the Roles of the p110α and p110β Isoforms of PI3K in Signaling and Cancer	55
Nina Ilić and Thomas M. Roberts	
Phosphatidylinositol 3-Kinase: The Oncoprotein	79
Peter K. Vogt, Jonathan R. Hart, Marco Gymnopoulos, Hao Jiang, Sohye Kang, Andreas G. Bader, Li Zhao, and Adam Denley	
AKT Signaling in Physiology and Disease	105
Krishna M. Vasudevan and Levi A. Garraway	
Faithfull Modeling of <i>PTEN</i> Loss Driven Diseases in the Mouse	135
Caterina Nardella, Arkaitz Carracedo, Leonardo Salmena, and Pier Paolo Pandolfi	
PI3K as a Target for Therapy in Haematological Malignancies	169
Asim Khwaja	
Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors	189
Carlos L. Arteaga	

From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development	209
Saveur-Michel Maira, Peter Finan, and Carlos Garcia-Echeverria	
New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)	241
Morris E. Feldman and Kevan M. Shokat	
Small Molecule Inhibitors of the PI3-Kinase Family	263
Zachary A. Knight	
Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance	279
Qi-Wen Fan and William A. Weiss	
Index	297